BioCentury
ARTICLE | Clinical News

uniQure gets bump on latest hemophilia readout

February 8, 2019 6:36 PM UTC

uniQure N.V. (NASDAQ:QURE) added $3.31 (10%) to $36.49 Friday after new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061 to treat hemophilia B. Separately, the company said Monday it had dosed the first patient in the Phase III HOPE-B study of the therapy.

Friday's data update showed that among three patients with severe disease, mean Factor IX levels rose to 38% of normal 12 weeks after a single IV administration, from 31% six weeks after the therapy was given. uniQure shares had risen 36% on Nov. 15, 2018, when it reported the six-week data in an interim update (see "uniQure Gains on Factor IX Activity Data for Hemophilia B Gene Therapy")...